ReviewJournal of cancer research and clinical oncology2015
Oncogenes associated with drug resistance in ovarian cancer.
Review in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 46 citations in OpenAlex.
- Identification of genes predicting chemoresistance and short survival in ovarian cancer.Translational cancer research · 2024Article
- A Non-Disposable Electrochemical Sensor Based on Laser-Synthesized Pd/LIG Nanocomposite-Modified Screen-Printed Electrodes for the Detection of HSensors (Basel, Switzerland) · 2024Article
- Antioxidant, Anti-Inflammatory and Anti-Proliferative Properties ofPlants (Basel, Switzerland) · 2023Article
- Diallyl trisulfide alleviates chemotherapy sensitivity of ovarian cancer via the AMPK/SIRT1/PGC1α pathway.Cancer science · 2023Article
- In Vitro Models of Ovarian Cancer: Bridging the Gap between Pathophysiology and Mechanistic Models.Biomolecules · 2023Review
- Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022.Frontiers in oncology · 2023Review
- Potential clinical utility of liquid biopsies in ovarian cancer.Molecular cancer · 2022Review
- Long non-coding RNAs regulate drug resistance in cancer.Molecular cancer · 2020Review
- Exploring cisplatin resistance in ovarian cancer through integrated bioinformatics approach and overcoming chemoresistance with sanguinarine.American journal of translational research · 2020Article
- New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.Journal of experimental & clinical cancer research : CR · 2019Article
- Mining Featured Biomarkers Linked with Epithelial Ovarian CancerBased on Bioinformatics.Diagnostics (Basel, Switzerland) · 2019Article
- Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies.Translational oncology · 2018Article
- Low expression of KCNN3 may affect drug resistance in ovarian cancer.Molecular medicine reports · 2018Article
- Shikonin induces mitochondria-mediated apoptosis and attenuates epithelial-mesenchymal transition in cisplatin-resistant human ovarian cancer cells.Oncology letters · 2018Article
- Interaction between CD133 and PI3K-p85 promotes chemoresistance in gastric cancer cells.American journal of translational research · 2018Article
- LC-MS Based Sphingolipidomic Study on A2780 Human Ovarian Cancer Cell Line and its Taxol-resistant Strain.Scientific reports · 2016Article
- Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling.Journal of biological research (Thessalonike, Greece) · 2015Article
- A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.Molecular cancer · 2015Article
- Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOncogenes play pivotal roles in the development of cancer, and disturbances in their expression have been implicated in drug resistance. However, an overview of the contribution of oncogenes to drug resistance in ovarian cancer has not previously been reported. This study aimed to review the drug resistance-related oncogenes in ovarian cancer and precisely determine their relationships.
methodsThe oncogenes associated with drug resistance in ovarian cancer from available papers were summarized, and a comprehensive bioinformatics analysis including pathway enrichment, biological processes annotation, protein/gene interaction and microRNA-mRNA interaction was performed.
resultsTotal of 25 oncogenes contributing to drug resistance in ovarian cancer was integrated and further analyzed. An oncogene-mediated drug resistance pathway that explains the associations of 21 of these oncogenes in drug resistance was drafted on the basis of previously published papers. The downstream location of v-akt murine thymoma viral oncogene (AKT) and B-cell CLL/lymphoma 2-associated X protein (BAX) with respect to many other oncogenes was determined, indicating that the two genes may play a central role, and the AKT- and BAX-mediated signaling are the main pathways accounting for the involvement of oncogenes in drug resistance in ovarian cancer. Besides, the annotation of biological process indicated that the apoptosis (cell death) and phosphorylation (phosphate metabolic process) might be the two major biological routes through which oncogenes contribute to drug resistance in ovarian cancer. In addition, on the basis of the comprehensive analysis of microRNA-mRNA interactions, 11 microRNAs were identified to be targeted at least 7 of the 25 oncogenes, indicating that those microRNAs could be an important regulator of the 25 oncogenes. Collectively, by integrating and further analyzing the available data on these oncogenes, this study contributes to improving our understanding of the mechanisms by which their expression leads to drug resistance in this ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.